Have you been burned by penny stocks?
pump & dump advice
scam stock picks
dishonest promoters
low quality companies
biased newsletters
bad tips from friends
There is a better (and more profitable) way! Get top picks in excellent quality penny stock companies straight from the authority.
Peter Leeds is the Authority on penny stocks!
Peter Leeds is the author of Penny Stocks for Dummies, and Invest in Penny Stocks.

The publisher, John Wiley & Sons, is a $3 billion corporation, and they only allow their name to be associated with each industry's best authority. They would only work with Peter Leeds.

Wiley approached Peter Leeds to write Invest in Penny Stocks. Given the strong demand for advice, they next contracted him to produce Penny Stocks for Dummies under their flagship Dummies brand.
You get top Penny Stock picks with no cost, no risk.
No commitment, cancel any time!

No Spam. No Advice. Complete Data Privacy.

Only Top Quality Companies! Any stock which makes the Peter Leeds newsletter must first pass exhaustive 29 point Leeds Analysis, which delves deep into their balance sheet, growth trends, management team, financial ratios, and much more...
Get the honesty and integrity which Peter Leeds brings to investing.
Peter Leeds guarantees that neither he nor any of his team members accept a single penny of compensation from the stocks they profile. In over 20 years they have never had hidden motivations or a conflict of interest. You will NOT find this ANYWHERE else.

Be Warned!! The majority of financial newsletters are paid advertisements in disguise!
You instantly get full, unlimited access:
• penny stock picks from the Authority, Peter Leeds
• you save hours with buy/sell price opinions
• you keep informed with daily updates
• more than 50 bonus articles to multiply your trading skills
• you start fast with the Quick Start Package
• profit from the newsletter's full analysis team

You want the best - after all, anything less can cost you money. The picks are not advice.
New subscriptions are limited to 250 per month!
The first step to changing your life is simple - click on the green button to start your free trial. Why not start immediately?

Makes a great INSTANT gift! Get a subscription for the investor in your life!
You want to make the most of a small amount of money.
This is the way to do it.
Peter Leeds, The Penny Stock Professional
Steve Kohr
Hi Peter, wanted your thoughts on the Sept 24th pick. I see an earnings report coming out next week...in preparation of this, what are your opinions in regards to this company moving forward....Thanks!
Peter Leeds, The Penny Stock Professional We love these guys, and are expecting good numbers. We can't know for sure until the actual release, but based on the price spike over the last few days, either the masses are expecting the same thing, or management are insider trading, since they know the numbers will be great. Short term, anything can happen. Long term, they should do incredibly for Peter Leeds subscribers AGAIN.
Steve Kohr Awesome, thanks Peter!
Peter Leeds, The Penny Stock Professional
Peter Leeds, The Penny Stock Professional

Why They Call It Dope

by Ed Zwirn

Read all the past Blog entries here

Bayer Pharmaceutical Products advertisementIn 1874, chemist C.R. Adler Wright synthesized diacetylmorphine in his London laboratory by adding two acetyl groups to the molecule morphine, which is found naturally in the opium poppy. The new wonder drug was itself an inactive drug, but when inserted into the body it rapidly converted into morphine.

Morphine at the time had been in widespread use, at least in the United States, since the Civil War, when it was basically the only pain killer available for battlefield injuries. In the decades to follow, veterans (and many others) continued to use morphine, for both pain relief and "recreational" purposes, many becoming addicted along the way.

In 1895, the German drug company Bayer marketed diacetylmorphine as an over-the-counter drug under the trade name Heroin. They got the name from the Greek word "heros" because of its perceived "heroic" effects upon a user. It was developed mainly as a morphine substitute for cough suppressants. As can be seen in the trade advertising of the era, Bayer considered its new drug one of its patented stars (along with aspirin) and marketed it as a "non-addictive morphine substitute." It wasn't until 1913, after the high addiction rates associated with its use became obvious, that Bayer ceased heroin manufacture.

It is useful to recall amidst all the attention given to attempts to liberalize marijuana laws throughout the country that this liberalization represents only a slight backward swing in pendulum of U.S. drug policy. Just about 100 years ago, Americans could purchase any drug they wanted over the counter, without fear of legal repercussion or the need for a doctor's prescription.

According to my New Oxford American Dictionary, the word "dope" has its origins in the early 18th century, when it referred to a "thick, gooey liquid." Dopes were commonly sold in combination hardware-drug stores, establishments in which customers could purchase everything from "pipe dope" for plumbing jobs to tonics for depressed women, and hang out with other upstanding citizens at the soda fountain, where they could drink Coca-Cola, which until 1903 included an estimated dose of nine milligrams of cocaine per serving.

There are probably no accurate figures on drug use, misuse and addiction during this free-for-all period, but one thing is certain: Many Americans back at the turn of the loast century were getting pain relief (or a good high) and off of substances they would do time for possessing today, and this was considered a health issue, with no law enforcement or prison involvement.

The party started to come to an end in 1906, when the Pure Food and Drug Act took effect, requiring the labeling of "habit-forming" and "deleterious" substances, including heroin, cocaine and marijuana. This labeling, after which many innocent users of tonics, cough medicines and other "dope" could no longer claim innocence, lessened the social acceptability of these drugs while increasing awareness of their side effects, and led to the eventual curtailment of their production and criminalization of possession and use.

The decade of the 1920s saw this criminalization trend going even further, with the passage of an amendment to the U.S. Constitution banning alcohol. By the 1930s, at the nadir of the Great Depression, this attempt at sobriety had been abandoned. Even though Prohibition undoubtedly lowered the consumption of alcoholic beverages while it was in effect, it had become widely unpopular among people who liked to drink, and because of the gangster era it had spawned, and the public was desperate in any case for ways to increase economic activities and benefit tax coffers.

It wasn't until 1937, a few years after the repeal of Prohibition, that growing and using marijuana became illegal under federal and state laws. From 1850 to 1941, cannabis was included in the U.S. Pharmacopoeia as a recognized medicine. In 1970, spurred on in part by President Richard Nixon's widely touted "war on drugs," the U.S. Congress decided that marijuana lacked medicinal value and was an illegal substance. The Controlled Substance Act of that year decided that MJ (along with LSD and heroin) was a Schedule I substance, having the highest potential for abuse and no medicinal value. Drugs in schedules II through V, which are considered less dangerous than marijuana, include opium, cocaine and amphetamine.

This misalignment of U.S. drug policy is beginning to reverse itself, at least on the state and local levels of government. Some 23 states and the District of Columbia now allow some degree of medical and/or recreational MJ use and the coming election will see voters in seven states, one U.S. territory and at least 17 cities and counties face a marijuana initiative when they go to the polls.

Drug store soda fountainThe quaint remembrances we have of the U.S. of 100 years ago often include a nostalgic look at the drug store soda fountains of yore without a full appreciation of what may have been going on at these community watering holes. A future generation may well look back at cannabis dispensaries in much the same way. As the MJ business (in all its legal and illegal manifestations) mainstreams, and revenues guessed to be at least $40 billion annually in the U.S. go legit, it's important to remember why they call it "dope." It's named after all the stupid laws that regulate it.

 

 


 

Penny Stock Trading Newsletter, $195/yr

Our penny stock trading newsletter specializes in high quality shares under $5.

Profit as we reveal the best undiscovered companies of the highest quality. We do not provide individual advice. These low-priced shares are trading for $5 or less, some as little as a few pennies.

All picks:

  • Have passed 29 Point Leeds Analysis
  • Are High Quality Companies
  • Are Our Best Picks Ready to Increase in price

Each of our penny stock trading picks has passed Leeds Analysis and is much more likely to multiply in value in the short term. As we say, great quality always rises to the top!

DID YOU KNOW?

Peter Leeds and his team take no compensation from the companies they review. (Most other newsletters do, especially the free ones. How can you trust them?)

All Peter Leeds high quality penny stock picks come with the 100% Unbiased Guarantee, stating that our research is completely impartial.

Your Penny Stock Trading Advantage

When it comes to the best companies to buy, Peter Leeds is the only choice. With a full team, you will be shown opinions on which companies are best, and gain instant access to all the daily updates, full company reports, and buy and sell prices.

In fact, if you want to try any of the numerous, unproven, flash-in-the-pan services, you are truly putting your money at risk. Selecting the best companies is something that Peter Leeds and his team take very seriously, and now you can benefit from all their hard work for an extemely low price!

The best picks to buy are the ones profiled by Peter Leeds! Get started with high quality stocks to buy right now - free and instant!

High Quality Penny Stocks

When you start your free trial you will get:

  • new picks weekly
  • buy/sell trading prices
  • daily updates
  • full company reports
  • 50+ bonus trading articles
  • phone and e-mail support

After the newsletter trial, you will be billed $195 for your annual subscription fee. Of course, there is zero risk and no commitment. If you don't like what you see with your trial, simply cancel and owe nothing! (Most people see what the free trial has to offer and do not cancel, but that is entirely up to you).

We do not provide individual advice.

Even if you are brand new to trading, you will get all the tools you need to be successful.

And don't forget - when it comes to the best high quality stocks, Peter Leeds and his team are the most well known, most trusted source for investors to learn which shares to buy.

Remember, Peter Leeds and his team have:

  • Been around for over two decades!
  • Sold well over 35,000 subscriptions
  • Been featured across all top media

This is a group who truly know what they are doing!

Peter Leeds strictly maintains that all of his employees abide by the ethics and moral code he leads with. There has never been, nor will there even be, a single penny in compensation for any of the stocks they profile. In this way, you know you can trust the honesty and integrity which the Peter Leeds newsletter brings to bear.

Start your free 14 day trial now! Access is instant, and trials provide the full Peter Leeds service, including high quality picks, price targets, and daily trading updates.

Copyright © 2014 PeterLeeds.com | Bent Digital Media Design